Amivantamab-vmjw was approved with carboplatin and pemetrexed for locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, according to a March 1 news release from the agency.
It is the only drug approved for these mutations, MedPage reported March 4.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
